Artiva Biotherapeutics (ARTV) Other Non-Current Liabilities (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly Other Non-Current Liabilities of $73000.0 for Q4 2024, little changed year-over-year from $73000.0 in Q1 2024, and little changed quarter-over-quarter from $73000.0 in Q3 2024.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Other Non-Current Liabilities for 2 consecutive years, with $73000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Non-Current Liabilities changed 0.0% year-over-year to $73000.0; the TTM figure through Dec 2024 stood at $73000.0 (changed 0.0% YoY), while the FY2024 annual figure was $73000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities steadied at $73000.0 in Q4 2024 per ARTV's latest filing, from $73000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $74000.0 in Q2 2024 and bottomed at $73000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 73,000.00 |
| Jun 30, 2024 | 27.72 Mn |
| Dec 31, 2023 | 25.10 Mn |